Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift toward multi-cancer detection.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated ...

Bonello covers the Healthcare sector, focusing on stocks such as GeneDx Holdings, Natera, and Guardant Health. The word on The Street in general, suggests a Strong Buy analyst consensus rating for ...

Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company’s revenue for the quarter was up 33.9% compared to the same quarter last year.